Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma

@article{Mrcs2015IsolatedLP,
  title={Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma},
  author={Henry G. Smith Mrcs and J. Cartwright Mrcs and Michelle J. Wilkinson Mrcs and Dirk C. Strauss Frcs and J. Meirion Thomas Frcs and PhD A. J. Hayes FRCS},
  journal={Annals of Surgical Oncology},
  year={2015},
  volume={22},
  pages={356-361}
}
Isolated limb perfusion (ILP) is indicated in locally advanced melanoma and soft tissue sarcoma of the extremities. This series reports the outcome of patients undergoing ILP with melphalan and tumour necrosis factor α (TNFα) at a single centre. All patients undergoing ILP from January 2005 to January 2015 were identified from a prospectively maintained database. Those undergoing ILP for in-transit melanoma (ITM) were grouped according to disease burden: low volume and bulky (>2 cm diameter). A… CONTINUE READING

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 1 EXCERPT

Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas

JP Deroose, AM Eggermont, +3 authors JH de Wilt
  • J Clin Oncol
  • 2011

Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters

HR Alexander, Jr., +4 authors P Soriano
  • J Clin Oncol
  • 2010